Condensed Consolidated Statements of Comprehensive Loss - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Revenues:
Product sales	$ 2,260,994	$ 2,648,657	$ 3,140,604
License fee and other revenues	386,941	1,250,000	4,623,333
Research and development	585,312	1,754,434	1,277,668
Total revenues	3,233,247	5,653,091	9,041,605
Costs and Expenses:
Costs of goods sold	1,159,173	264,915	338,572
Costs of license fee and other revenues			1,189,170
Research and development	53,492,471	41,735,888	33,680,158
Sales and marketing	1,027,139	768,871	1,132,921
General and administrative	6,562,555	9,102,926	8,281,025
Total costs and expenses	62,241,338	51,872,600	44,621,846
Operating loss	(59,008,091)	(46,219,509)	(35,580,241)
Interest expense	(5,479,821)	(2,090,750)
Interest and other income, net	337,901	245,705	55,916
Foreign currency transaction (loss) gain, net	(39,538)	(1,188)	938
Loss before income tax	(64,189,549)	(48,065,742)	(35,523,387)
Income tax benefit (expense)	5,053,833	(58,229)	(7,791)
Net loss	(59,135,716)	(48,123,971)	(35,531,178)
Less: Net loss attributable to noncontrolling interest	(98,766)	(121,605)	(105,352)
Net loss attributable to Immunomedics, Inc. stockholders	$ (59,036,950)	$ (48,002,366)	$ (35,425,826)
Loss per common share attributable to Immunomedics, Inc. stockholders (basic and diluted):	$ (0.62)	$ (0.51)	$ (0.42)
Weighted average shares used to calculate loss per common share, (basic and diluted)	94,770,172	93,314,872	84,631,567
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustments	$ 1,192	$ (434,617)	$ 100,094
Unrealized gain (loss) on securities available for sale	27,674	11,688	(87)
Other comprehensive income (loss)	28,866	(422,929)	100,007
Comprehensive loss	(59,106,850)	(48,546,900)	(35,431,171)
Less comprehensive loss attributable to noncontrolling interest	(98,766)	(121,605)	(105,352)
Comprehensive loss attributable to Immunomedics, Inc. stockholders	$ (59,008,084)	$ (48,425,295)	$ (35,325,819)